Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.86%122.371.1%$687.52m
GILDGilead Sciences, Inc.
-1.28%80.170.9%$652.57m
AMGNAmgen Inc.
-1.33%180.531.1%$453.70m
BIIBBiogen Inc.
-2.83%328.551.2%$418.30m
REGNRegeneron Pharmaceuticals, Inc.
-0.05%432.762.7%$322.07m
VRTXVertex Pharmaceuticals Incorporated
-2.31%151.061.9%$219.47m
INCYIncyte Corporation
-0.62%113.482.5%$198.97m
ALXNAlexion Pharmaceuticals, Inc.
-2.75%135.201.9%$188.62m
ILMNIllumina, Inc.
0.80%211.553.5%$133.98m
ALNYAlnylam Pharmaceuticals, Inc
0.76%115.5710.7%$131.21m
EXELExelixis, Inc.
-0.70%26.986.5%$126.80m
BLUEBluebird Bio, Inc.
-1.54%140.3517.3%$119.91m
SRPTSarepta Therapeutics, Inc.
-0.91%51.4716.9%$110.18m
BMRNBioMarin Pharmaceutical Inc.
-1.47%86.464.4%$109.02m
CLVSClovis Oncology, Inc.
-2.49%75.5716.5%$96.52m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.